Viraj Degaonkar

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Thomas Powles, Zoe J. Assaf, Nicole N. Davarpanah et al. · Nature · 2021 · 578 citations

Adjuvant Immunotherapy, Cancer Immunosurveillance, Urology +1

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend et al. · The Lancet Oncology · 2021 · 393 citations · Full text

Urology, Versus Observation, Genitourinary Cancer +6

Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma

Thomas Powles, Zoe J. Assaf, Viraj Degaonkar et al. · European Urology · 2023 · 112 citations

Urology, Overall Survival, Genitourinary Cancer +6

Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma

Alexandra Drakaki, Preet K. Dhillon, Heather A. Wakelee et al. · OncoImmunology · 2020 · 59 citations · Full text

IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).

Maha Hussain, Thomas Powles, Peter Albers et al. · Journal of Clinical Oncology · 2020 · 51 citations

Surgical Oncology, Immunology, Immunotherapeutics +19